Hepatitis B Virus News and Research

RSS

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

...

8 Oct 2013

Vaccination campaign led HBV to more than double rate of "breakout" mutations

A universal infant vaccination campaign in China has led the Hepatitis B virus (HBV) to more than double its rate of "breakout" mutations. These mutations may enable the virus to elude the vaccine, necessitating new vaccination strategies.

8 Oct 2013

New injection device delivers optimum treatment dose to hepatitis C patients

A new injection device, ViraferonPeg Clearclick, has launched in the UK today for hepatitis C patients to accurately titrate and self-administer their weekly dose of ViraferonPeg (peginterferon alfa-2b).

5 Oct 2013

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

New data from Boehringer Ingelheim's hepatitis C virus clinical development program have been accepted for presentation at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 1-5 in Washington, D.C.

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Canada should begin screening 'Baby Boomers' for the hepatitis C virus infection, since this age group is likely the largest group to have the illness, and most don't know they have it, say a group of liver specialists in the Toronto Western Hospital Francis Family Liver Clinic. Unlike many other chronic viral infections, early treatment makes hepatitis C curable.

1 Oct 2013

Study: Higher rates of acute hepatitis C virus clearance are seen in women

A study of patients infected with acute hepatitis C virus (HCV) infection found that women had higher rates of spontaneous viral clearance—undetectable levels of the virus without initiating drug therapy.

13 Sep 2013

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Boehringer Ingelheim today announced the completion of patient enrolment for a Phase IIa clinical trial investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus infection.

10 Sep 2013

Medivir, Daewoong Discontinue HBV Drug Development

...

6 Sep 2013

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

The hepatitis C virus hijacks the body's immune system, leaving T cells unable to function. A new study in animal models suggests that blocking a protein that helps the virus thrive could restore immune function, allowing the body to fight infection. The work, led by teams at The Research Institute at Nationwide Children's Hospital and Emory University, was published online Aug. 26 in the Proceedings of the National Academy of Sciences.

4 Sep 2013

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.

4 Sep 2013

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Treatment of chronic hepatitis C virus genotype 1 infection with the interferon-free regimen of sofosbuvir and ribavirin resulted in a high sustained virologic response rate in a patient population with unfavorable treatment characteristics, according to a study in the August 28 issue of JAMA.

28 Aug 2013

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

Boehringer Ingelheim today announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete.

15 Aug 2013

New findings may lead to first new animal model for hepatitis C virus

By differentiating monkey stem cells into liver cells and inducing successful infection, researchers from the Icahn School of Medicine at Mount Sinai have shown for the first time that the hepatitis C virus can replicate in monkeys, according to research published in the journal Gastroenterology.

3 Aug 2013

Study: About 50% of fibromyalgia patients have nerve damage

About half of a small group of patients with fibromyalgia - a common syndrome that causes chronic pain and other symptoms - was found to have damage to nerve fibers in their skin and other evidence of a disease called small-fiber polyneuropathy (SFPN). Unlike fibromyalgia, which has had no known causes and few effective treatments, SFPN has a clear pathology and is known to be caused by specific medical conditions, some of which can be treated and sometimes cured.

31 Jul 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

26 Jul 2013

Combination treatment can reduce hepatitis C infection in people who inject drugs

The burden of liver disease could be dramatically reduced by scaling up the combination of interventions for hepatitis C infection among people who inject drugs according to University of Bristol researchers. The findings, published today [24 July], form part of new global recommendations on treating the virus.

25 Jul 2013

Combination of 6 comprehensive measures to prevent spread of hepatitis C

UC San Francisco researchers are recommending a combination of six comprehensive measures to prevent the spread of hepatitis C, in an effort to address the more than 31,000 young people they estimate may be newly infected with the virus each year in the United States due to injection-drug use.

25 Jul 2013

Hepatitis B Virus News and Research

J&J's Janssen Buys Rights To Hepatitis C Compound From GSK

Vaccination campaign led HBV to more than double rate of "breakout" mutations

New injection device delivers optimum treatment dose to hepatitis C patients

Data from Boehringer Ingelheim's HCV clinical program accepted for presentation at The Liver Meeting

Merck & Co. Axes 8,500 In R&D Restructuring

Canada should start screening 'Baby Boomers' for hepatitis C virus infection, say liver specialists

Study: Higher rates of acute hepatitis C virus clearance are seen in women

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Medivir, Daewoong Discontinue HBV Drug Development

Blocking a protein helps virus to thrive and restore immune function to fight HCV infection

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

HCV treatment with sofosbuvir and ribavirin results in sustained virologic response

Boehringer Ingelheim completes patient enrolment of two pivotal Phase III interferon-free hepatitis C clinical trials

New findings may lead to first new animal model for hepatitis C virus

Study: About 50% of fibromyalgia patients have nerve damage

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

Combination treatment can reduce hepatitis C infection in people who inject drugs

Combination of 6 comprehensive measures to prevent spread of hepatitis C

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News